New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

The deal reflects Nordic’s bet on artificial-intelligence advancements in healthcare.

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

A free pet wellness clinic offering vaccines and microchips will be held June 28 in East Cleveland for Cleveland and East ...

The stock's fall snapped a four-day winning streak.

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

Demand for validated consumables and innovative testing methods like PCR and chromatography persists, driven by regulatory needs and environmental considerations Biopharmaceuticals Manufacturing ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).